– “ArtemiC” is a nutraceutical oral spray designed to aid in the recovery from severe COVID-19 symptoms.
New Delhi, January 16, 2022: HempStreet, a leading medicinal cannabis venture in India, has partnered with MGC Pharma, a UK-based pharmaceuticals company, to launch ArtemiC, a nutraceutical mouth spray designed to aid in the recovery of patients with severe COVID-19 symptoms. This innovative product is the result of the partnership announced between the two companies earlier this year, where MGC Pharma’s expertise in polyherbal formulations based on cannabis and other phytopharmaceuticals was combined with HempStreet’s research to retail approach to bring ArtemiC to the market.
HempStreet, a company founded in 2019 with a mission to blend ancient Ayurvedic knowledge with modern cannabis research to provide sustainable and affordable solutions for widespread health issues, has partnered with MGC Pharma to develop and launch ArtemiC, a nutraceutical mouth spray. This product is specifically designed to alleviate the symptoms of long COVID-19, which continues to affect a significant number of individuals in India. This collaboration aims to create a range of phytopharmaceutical products to address mass ailments, leveraging the expertise of both companies.
Consisting of natural ingredients such as Curcumin, Boswellia serrata, Artemisinin, and Vitamin C, ArtemiC comes in two variations – ArtemiC Rescue, which is intended as an adjunctive treatment for COVID-19 symptoms, and ArtemiC Support, a daily supplement without Artemisinin. Clinical trials have shown that ArtemiC may reduce the severity of symptoms and lower the levels of C-reactive protein (CRP), a marker of inflammation related to COVID-19. Both variations of ArtemiC will be available through medical practitioners and leading pharmacies.
Commenting on the launch, Abhishek Mohan, Founder & CEO of HempStreet, said, “HempStreet and MGC Pharma are committed to bringing thoroughly studied, incredibly effective, and ethically dispensed phytomedicines to treat widespread illnesses that affect people worldwide. An observational open-label controlled clinical trial of ArtemiC, showed that the formulation demonstrated its efficacy in treating patients with severe COVID-19 for the first time. An estimated 15 million people in India are said to be suffering from “long covid” symptoms, making it a hidden mass ailment on its own. We look forward to helping patients nationwide with our products.”
Further, Roby Zomer, Managing Director and CEO of MGC Pharma, said, “Entry into significant global markets such as India is paramount to MGC Pharma’s strategy of advancing phytomedicine adoption globally. The latest observational trial results have expanded the possibilities for using ArtemiC in patients with severe COVID-19. In addition, working with HempStreet has facilitated access to our proprietary plant inspired medicines for millions of people in India who are still affected by the symptoms of COVID-19. MGC Pharma has always placed the treatment of patients at the heart of everything we do, and these results are promising signs for those who the disease has most severely impacted.“
HempStreet is leading the way in developing sustainable and economical solutions for mass ailments by blending ancient Ayurvedic techniques with modern cannabis research. The company has formed partnerships with Ayurvedic doctors and in collaboration with Amrita School of Ayurveda, is developing clinically supported solutions to tackle various health issues. Recently, HempStreet also expanded its product offerings by introducing Sarpagandha Vati, an Ayurvedic formulation to manage hypertension and insomnia.
